GDTC
CytoMed Therapeutics·NASDAQ
--
--(--)
--
--(--)
1.04 / 10
Underperform
Fundamental metrics indicate poor status (1.0/10). Bullish considerations: Inventory turnover ratio and Interest coverage ratio (EBIT / Interest expense) (%), balanced by issues in Net profit / Total profit (%) and Operating revenue (YoY growth rate %). Final rating: challenging.
Analysis Checks(3/5)
Total operating revenue (YoY growth rate %)
Value294.67
Score3/3
Weight-12.02%
1M Return0.88%
Value294.67
Score3/3
Weight-12.02%
1M Return0.88%
Interest coverage ratio (EBIT / Interest expense) (%)
Value27.60
Score2/3
Weight16.15%
1M Return-1.25%
Value27.60
Score2/3
Weight16.15%
1M Return-1.25%
Net profit / Total profit (%)
Value100.00
Score1/3
Weight20.03%
1M Return-1.59%
Value100.00
Score1/3
Weight20.03%
1M Return-1.59%
Inventory turnover ratio
Value38.02
Score2/3
Weight15.51%
1M Return-1.23%
Value38.02
Score2/3
Weight15.51%
1M Return-1.23%
Operating revenue (YoY growth rate %)
Value392.77
Score0/3
Weight60.33%
1M Return-5.31%
Value392.77
Score0/3
Weight60.33%
1M Return-5.31%
Total operating revenue (YoY growth rate %)
Value294.67
Score3/3
Weight-12.02%
1M Return0.88%
Value294.67
Score3/3
Weight-12.02%
1M Return0.88%
Inventory turnover ratio
Value38.02
Score2/3
Weight15.51%
1M Return-1.23%
Value38.02
Score2/3
Weight15.51%
1M Return-1.23%
Interest coverage ratio (EBIT / Interest expense) (%)
Value27.60
Score2/3
Weight16.15%
1M Return-1.25%
Value27.60
Score2/3
Weight16.15%
1M Return-1.25%
Operating revenue (YoY growth rate %)
Value392.77
Score0/3
Weight60.33%
1M Return-5.31%
Value392.77
Score0/3
Weight60.33%
1M Return-5.31%
Net profit / Total profit (%)
Value100.00
Score1/3
Weight20.03%
1M Return-1.59%
Value100.00
Score1/3
Weight20.03%
1M Return-1.59%
Is GDTC undervalued or overvalued?
- GDTC scores 1.04/10 on fundamentals and holds a Premium valuation at present. Backed by its -27.59% ROE, 0.00% net margin, -4.52 P/E ratio, 2.23 P/B ratio, and -22.41% earnings growth, these metrics solidify its Underperform investment rating.
